Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-stratified optimization of hematopoietic stem cell transplantation and chemotherapy for acute myeloid leukemia
ChiCTR-OCH-12003020Phase 2Completed
- Sponsor
- Peking University Institute of Hematology
- Start
- Jan 2013
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous hematopoietic stem cells, allogeneic hematopoietic stem cell transplantation and cytarabine in acute myeloid leukemia (AML) (4 arms), sponsored by Peking University Institute of Hematology. Primary endpoints: Leukemia-free survival and Overall survival. Started Jan 2013; status: completed.
02
Drugs
autologous hematopoietic stem cellsallogeneic hematopoietic stem cell transplantationcytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-OCH-12003020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OCH-12003020.